{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Woo HY"],"funding":["Ministry of Science and ICT","Roche Korea"],"pagination":["e0270716"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9307167"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(7)"],"pubmed_abstract":["<h4>Aims</h4>Induction of a durable viral response is difficult to achieve in patients with chronic hepatitis B (CHB), even from long-term use of a nucleos(t)ide analogue (NA). This study investigated whether switching to peginterferon (PegIFN) alfa-2a after long-term NA therapy induced a durable viral response.<h4>Methods</h4>Patients with hepatitis B e antigen (HBeAg)-positive CHB who received any NA for at least 72 weeks and had a low level of HBV DNA (≤100 IU/mL) were randomized (1:1) to receive PegIFN alfa-2a (180 μg/week) or NA for 48 weeks. The primary endpoint was change in the hepatitis B surface antigen (HBsAg) titer during antiviral therapy.<h4>Results</h4>We randomized 149 CHB patients to the two groups. Compared to baseline, the HBsAg levels in both groups were not lower at we"],"journal":["PloS one"],"pubmed_title":["Effect of switching from nucleos(t)ide maintenance therapy to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomized trial."],"pmcid":["PMC9307167"],"funding_grant_id":["2021R1F1A1052110"],"pubmed_authors":["Chung WJ","Park JG","Lee YR","Hwang JS","Park YJ","Heo J","Tak WY","Lee HJ","Kweon YO","Park SY","Woo HY"],"additional_accession":[]},"is_claimable":false,"name":"Effect of switching from nucleos(t)ide maintenance therapy to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomized trial.","description":"<h4>Aims</h4>Induction of a durable viral response is difficult to achieve in patients with chronic hepatitis B (CHB), even from long-term use of a nucleos(t)ide analogue (NA). This study investigated whether switching to peginterferon (PegIFN) alfa-2a after long-term NA therapy induced a durable viral response.<h4>Methods</h4>Patients with hepatitis B e antigen (HBeAg)-positive CHB who received any NA for at least 72 weeks and had a low level of HBV DNA (≤100 IU/mL) were randomized (1:1) to receive PegIFN alfa-2a (180 μg/week) or NA for 48 weeks. The primary endpoint was change in the hepatitis B surface antigen (HBsAg) titer during antiviral therapy.<h4>Results</h4>We randomized 149 CHB patients to the two groups. Compared to baseline, the HBsAg levels in both groups were not lower at we","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-09T16:53:39.614Z","creation":"2022-08-07T23:45:09.736Z"},"accession":"S-EPMC9307167","cross_references":{"pubmed":["35867702"],"doi":["10.1371/journal.pone.0270716"]}}